Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | CCR5 | P51681 | 8/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | PPIA | P62937 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17155018 | 0.84 | KMT2A (0.37) | OPRL1OPRM1OPRD1CCR5KCNH2 | |
| SCHEMBL18406816 | 0.81 | OPRL1 (0.39) | OPRL1OPRM1OPRD1CCR5 | |
| SCHEMBL17155364 | 0.78 | CCR5 (0.39) | OPRL1OPRM1OPRD1CCR5KCNH2 | |
| SCHEMBL1197953 | 0.75 | HTR2A (0.42) | — | |
| SCHEMBL18411503 | 0.75 | CCR5 (0.39) | OPRL1OPRM1OPRD1CCR5KCNH2 | |
| SCHEMBL18406810 | 0.73 | KDM4E (0.40) | KCNH2 | |
| SCHEMBL17154890 | 0.72 | MC4R (0.32) | OPRL1OPRM1OPRD1CCR5 | |
| SCHEMBL17154975 | 0.71 | CCR5 (0.39) | CCR5 | |
| SCHEMBL17155201 | 0.69 | OPRL1 (0.38) | OPRL1OPRM1OPRD1CCR5 | |
| SCHEMBL17154908 | 0.68 | CCR5 (0.45) | OPRL1OPRM1OPRD1CCR5CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2017-01-26 | — | — | US | disclosed |
| WO-2015150557-A1 | MACROCYLIC PYRIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022201-A1 | MACROCYLIC PYRIDINE DERIVATIVES | VPS26B, VPS4B, VPS28 | OPRL1 3562/4885OPRM1 4590/4885OPRD1 3628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.